Stem Cell Clinic

Troy resident ‘gets it done’ with ground-breaking treatment – Troy Daily News

By Adult Stem Cells

For Miami Valley Today

TROY Bill Willoughby has always been an optimist. This positive approach to life would serve him well after being diagnosed with non-Hodgkins lymphoma in 2015.

I was going to a doctor and at one point he said with my condition, the best he could do was try to keep me in remission, explained Bill, a Troy resident. So, he referred me to Dr. Faber at OHC for a stem cell transplant. Being an optimist, I agreed and said, Im all in. Lets get it done.

Bill went to OHC for his chemotherapy followed by the stem cell transplant for his lymphoma. OHCs stem cell transplant experts have performed more than 2300 transplants since 1989.

Stem cell transplant is a life-saving option for many people with blood cancers, explained Edward Faber, Jr., MD, MS, an OHC medical oncologist, hematologist and transplant specialist. But for Bill, months later he relapsed and the cancer was in his lungs, liver and in his bones. Weve had excellent success with stem cell transplants. Unfortunately, there are some patients for whom it just doesnt work. Our entire team was sad to learn that Bill was one of those patients.

With the cancer now in his bones, Bill was experiencing more pain than before not good for someone who still hasnt retired from the building and rental property business. So, when Dr. Faber suggested another treatment option, Bill was again optimistic.

Bill was an ideal candidate for a relatively new treatment called chimeric antigen receptor T cell immunotherapy, or CAR-T, said Dr. Faber. This is a ground-breaking treatment that has demonstrated incredible outcomes in some patients for whom all hope was lost. OHC has been using CAR-T for almost a year now and were seeing positive results. Were hopeful this will be the case for Mr. Willoughby.

CAR-T is still relatively new for treating cancers. In fact, OHC is the only adult cancer practice in the region to offer CAR-T to adults with blood cancers. With CAR-T, doctors remove immune system cells from a patient, modify them in a lab so they will recognize and kill cancer cells, then infuse them back into the patient through an IV. The cells that are injected back into the patient stay in the body, becoming what some researchers refer to as living drugs in that they are ready to attack if that same cancer returns.

I had never heard of CAR-T when Dr. Faber told me about it, Bill said. He explained that it helps your immune system cells fight the cancer. So, I looked it up, especially because I was running out of options, and it seemed like a wonderful theory. They said Im the fourth OHC patient to get this treatment.

After completing his research and weighing his options, once again, Bills response was, Im all in. Lets get this done. Bill received his CAR-T treatment in July and today hes feeling good.

I had my last scan a few weeks ago and they said the cancer in my lungs is gone, the cancer in my liver has decreased, and I still have some spots in my bones but they too have decreased, Bill said. Ive started back to work. Ive been passionate about building and construction since I was 15 years old. Now Im 70 and Im still into it, although I mostly subcontract the work. But I have rental properties and still do that maintenance work.

CAR-T has demonstrated success like no other treatment before. It received breakthrough therapy designation from the Food and Drug Administration, which means the process for approval is moved along more quickly after initial clinical trials show strong results. The procedure is currently performed in a designated center, originally as a hospital inpatient procedure that is now being administered in a hospital outpatient department.

OHC is launching new clinical trials to determine if it can be given in a doctors office treatment suite setting, like OHC, said Dr. Faber. And soon, we hope to introduce clinical trials that will look to expand CAR-T to treat other cancers, like solid tumors.

We still have a way to go with CAR-T and other immunotherapies, but if its successful, it will forever change the way the world treats cancer. Its a whole new frontier for medicine, Dr. Faber added.

Ive always been an optimist and a Christian, and I look at this as a great thing thats happened to me, Bill added. So does my family. Ive already recommended it to a couple people I know whove also run out of options. I tell them to call Dr. Faber and see if he can get it for them. When your chances become limited and then you learn about this, you start to see a possible light at the end of the tunnel.

OHC is the only adult cancer group in the region to offer this advanced treatment to adults. For more information including an educational video, visit https://www.ohcare.com/service/car-t-cell-therapy/ or call (888) 649-4800.

Provided photo Pictured is OHC patient Bill Willoughby back at work thanks to CAR T-cell immunotherapy.

Willoughby undergoes stem cell transplant

See the article here:
Troy resident 'gets it done' with ground-breaking treatment - Troy Daily News

The unexpected functional diversity of reactive astrocytes – Baylor College of Medicine News

By Adult Stem Cells

When the brain is injured or diseased astrocytes are the first to respond. They become reactive and play roles that can be both beneficial and deleterious, but little is known about how these diverse responses to injury are regulated.

In his lab at Baylor College of Medicine, Dr. Benjamin Deneen, professor of neurosurgery and theCenter for Stem Cell and Regenerative Medicine, has long been studying astrocytes, the most abundant cells in the brain. In this publication, he and his colleagues reported surprising discoveries regarding both the generation and activity of the first responders to brain injury.

Reactive astrocytes are associated with most forms of neurological disorders, from acute injury to degeneration, but their contributions to disease are only now coming to light, Deneen said.

In the current study, Deneen and his colleagues focused on identifying a regulator of reactive astrocytes. They looked into nuclear factor I-A (NFIA), a known regulator of astrocyte development, and investigated whether it also was involved in the generation and regulation of reactive astrocytes.

First, they determined that NFIA is abundant in human pediatric and adult reactive astrocytes found in a host of neurological injuries. Then, to explore the role NFIA plays in the response of reactive astrocytes to injury, the researchers turned to mouse models. They generated mice in which NFIA was specifically eliminated in astrocytes, and compared the reactive astrocyte response of these NFIA-deficient mice to that of mice with NFIA, after different types of neurological injury.

The results were surprising, said Deneen, who holds the Dr. Russell J. and Marian K. Blattner Chair and is a member of the Dan L Duncan Comprehensive Cancer Center at Baylor. Until now, it was thought that, regardless of the type of injury or where it occurred in the central nervous system, reactive astrocytes would respond in the same way. Knocking out NFIA allowed us to uncover a previously unknown layer of functional diversity in reactive astrocytes.

When white matter injuries occurred in the spinal cord of NFIA-deficient mice, reactive astrocytes were generated and migrated toward the injury, but were not able to remodel the injured blood brain barrier as well as the reactive astrocytes of normal mice did. Consequently, the white matter was not repaired.

But when the researchers tested the response to a different form of injury in another region of the central nervous system a stroke in the cerebral cortex they observed something different. While normal mice (with NFIA) responded to stroke by producing reactive astrocytes that migrated toward the injury to repair the bleeding, NFIA-deficient mice did not generate reactive astrocytes and the injury was not healed. In both cases, in the spinal cord and in the cerebral cortex, the injury was not properly repaired, but the underlying reasons were different in each case.

These findings suggest that NFIAs function in reactive astrocytes is dependent upon the type of injury and brain region in which the injury occurs. In the cerebral cortex, NFIA is crucial for making reactive astrocytes, while in the spinal cord NFIA is important for sealing off leaking blood vessels. These results hint at an extensive reservoir of reactive astrocyte responses that vary according to form and location of injury, Deneen said.

In addition, the researchers began to define the molecular mechanisms underpinning the generation of reactive astrocytes. They found that NFIA directly regulates the production of thrombospondin 4, an essential regulator of the generation of reactive astrocytes that had been previously identified in the lab of co-author Dr. Chay T. Kuo, associate professor of cell biology and neurobiology at Duke University.

Although our study was conducted in mice and more research is needed, we think our findings may reflect what occurs in people, as NFIA also is abundantly present in reactive astrocytes in both pediatric and adult neurological injuries, Deneen said.

We also are interested in investigating the role NFIA plays in reactive astrocytes involved in neurodegenerative diseases, such as Alzheimers and Parkinsons disease. Its possible it has a completely different set of functions in these conditions, Deneen said.

The study appears in The Journal of Clinical Investigation.

Other contributors of this work include Dylan Laug, Teng-Wei Huang, Navish A. Bosquez Huerta, Yu-Szu Huang, Debosmita Sardar, Joshua Ortiz, Jeffrey C. Carlson, Benjamin R. Arenkiel, Carrie A. Mohila, Stacey M. Glasgow and Hyun Kyoung Lee. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Texas Childrens Hospital, Duke University and the University of California San Diego.

This work was supported by grants from the National Multiple Sclerosis Society (RG-1501-02756 and FG-1607-25417), the National Institutes of Health (NIH) (NS096096 and S071153), the National Heart, Lung, and Blood Institute (NHLBI), NIH (T32-HL902332) and the David & Eula Winterman Foundation MS Research Endowment.

By Ana Mara Rodrguez, Ph.D.

See more here:
The unexpected functional diversity of reactive astrocytes - Baylor College of Medicine News

Stem Cell Assay Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2017 2025 – Herald Space

By Adult Stem Cells

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/13462?source=atm

The undifferentiated biological cells that can differentiate into specialized cells are called as stem cells. In the human body during early life and growth phase, stem cells have the potential to develop into other different cell types. Stem cells can differ from other types of cells in the body. There are two types of stem cells namely the embryonic stem cells and adult stem cells. Adult stem cells comprise of hematopoietic, mammary, intestinal, neural, mesenchymal stem cells, etc. All stem cells have general properties such as capability to divide and renew themselves for long period. Stem cells are unspecialized and can form specialized cell types. The quantitative or qualitative evaluation of a stem cells for various characteristics can be done by a technique called as stem cell assay. The identification and properties of stem cells can be illustrated by using Stem Cell Assay. The new developments in the field of stem cell assay research related to the claim of stem cell plasticity have caused controversies related to technical issues. In the study of stem cell assay, most conflicting results arise when cells express stem cell characteristics in one assay but not in another. The most important factor is that the true potential of stem cells can only be assessed retrospectively. The retrospective approach refers to back drop analysis which provides quantitative or qualitative evaluation of stem cells. The development in embryonic & adult stem cells assay will be beneficial to the global stem cell assay market. Stem cell assays find applications in pharmaceutical & biotechnology companies, academic & research institutes, government healthcare institutions, contract research organizations (CROs) and others. The influential factors like chronic diseases, increased investment in research related activities, and technological advancements in pharmaceutical & biotech industry is anticipated to drive the growth of the global stem cell assay market during the forecast period. The cost of stem cell based therapies could be one of the major limiting factor for the growth of the global stem cell assay market.

Ask an expert at https://www.persistencemarketresearch.com/ask-an-expert/13462?source=atm

The global stem cell assay market has been segmented on the basis of kit type, application, end user and region. The global stem cell assay market can be differentiated on the basis of kit type into human embryonic stem cell kits and adult stem cell kits. The adult stem cell kit includes hematopoietic stem cell kits, mesenchymal stem cell kits, induced pluripotent stem cell kits (IPSCs), and neuronal stem cell kits. The adult stem cell kits are projected to witness the highest CAGR during the forecast period due to the ease of use, cost & effectiveness of this type of kit in stem cell analysis.

Based on application global stem cell assay market is based on drug discovery and development, therapeutics and clinical research. The therapeutics segment includes oncology, dermatology, cardiovascular treatment, orthopedic & musculoskeletal spine treatment, central nervous system, diabetes and others.

Depending on geographic segmentation, the global stem cell assay market is segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to contribute significant share to the global stem cell assay market. The stem cell assay market in Europe, has gained impetus from the government & industrial initiatives for stem cell based research and the market in Europe is expected to grow at a remarkable pace during the forecast period. The major players in the global stem cell assay market include GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix Inc., Stemcell Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

Request to view TOC at https://www.persistencemarketresearch.com/toc/13462?source=atm

See more here:
Stem Cell Assay Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2017 2025 - Herald Space

Fabry Heart Cells Grown in Lab Dish Give Hints to Cardiac Complications – Fabry Disease News

By Induced Pluripotent Stem Cells

Heart cells derived from patients stem cells and grown in a lab dish can reveal important clues about the development of heart ailments associated with Fabry disease.

The study, A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology, was published in Stem Cell Reports.

Fabry is a rare genetic disorder caused by mutations in the GLA gene. Located on the X chromosome, the gene provides instructions for the production of an enzyme called alpha-galactosidase A (alpha-GAL A).

These mutations typically affect the activity of alpha-GAL A, leading to the accumulation of a type of fat called globotriaosylceramide (GL-3) in different tissues and organs, including the heart, kidneys and nervous system, gradually compromising their normal function.

For this reason, most Fabry patients develop heart disease over the course of their lives, which may progress to heart failure, the most common cause of death among people living with the disorder.

A major obstacle for advancing therapy for patients with [Fabry disease] is the knowledge gap between the direct molecular consequences of alpha-GAL A deficiency in CMs [cardiomyocytes, or heart cells] and the cascade of events driving disease in the heart; the inaccessibility of CMs from patients precludes adequate investigation of these events, especially at early stages, the investigators wrote.

In a previous study, researchers describe the generation of induced pluripotent stem cells (iPSCs) from Fabry patients carrying nonsense mutations in the GLA gene. This gave them the possibility, for the first time, to study the impact of alpha-GAL A deficiency on heart cells derived from patients iPSCs grown in a lab dish.

(iPSCs are fully matured cells that are reprogrammed back to a stem cell state, where they are able to grow into any type of cell. A nonsense mutation is a mutation in which the alteration of a single nucleotide (the building blocks of DNA) makes proteins shorter.)

Investigators from Sanofi, in collaboration with researchers at the University of Manchester, further investigated the properties of heart cells derived from patients iPSCs. Their aim was to discover more clues about the molecular mechanisms involved in the development of heart disease linked to Fabry.

Functional and structural characterization experiments revealed that heart cells from Fabry patients had higher levels of GL-3, and showed a series of abnormalities in the way they responded to electrical stimuli and in how they regulated their calcium usage, compared to heart cells from healthy people serving as controls. Calcium is essential to coordinate the hearts function by contributing to the electrical signals involved in heart muscle contraction.

When researchers analyzed the protein contents of heart cells grown in a lab dish, they found these cells produced more than 5,500 different proteins. This analysis also showed that compared to controls, heart cells from Fabry patients produced large amounts of lysosomal membrane protein 2 (LIMP-2) and heat shock-related 70 kDa protein 2 (HSPA2/HSP70-2).

(LIMP-2 is a protein normally found on the membrane of lysosomes small structures within cells that accumulate, digest, and recycle materials that regulates their transport within cells; HSPA2/HSP70-2 is a protein involved in cellular quality control, participating in the folding of other proteins and targeting abnormal proteins for degradation.)

Heart cells from Fabry patients released high amounts of cathepsin F, a protein that helps breakdown materials being transported inside lysosomes, as well as HSPA2/HSP70-2. As expected, when researchers corrected the genetic mutation associated with Fabry in heart cells derived from patients iPSCs, all these defects were reversed.

To confirm the validity of these proteins as Fabry biomarkers, researchers then forced healthy heart cells to produce high amounts of LIMP-2. They discovered this also triggered the release of large amounts of cathepsin F and HSPA2/HSP70-2, resulting in a massive accumulation of vacuoles (enclosed compartments filled with water and other substances) inside cells.

In summary, our study has shown the power of the iPSC model to reveal early functional changes and the development of a distinctive biomarker expression profile in [Fabry disease] CMs. These biomarkers may be of utility in drug screening and in elucidating the earliest pathological events and cascades in [Fabry disease] cells. Quantification in patient plasma and urine samples will be an important next step toward validating their relevance in patients, the researchers wrote.

A better understanding of these mechanisms will no doubt accelerate the development of more effective and increasingly personalized therapies for patients, they added.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Read more:
Fabry Heart Cells Grown in Lab Dish Give Hints to Cardiac Complications - Fabry Disease News

God of miniscule things – Pune Mirror

By Embryonic Stem Cells

Chug some fine brews as you soak up the science behind gene editingStem cells, which have the unique ability to morph into different types of cells, fascinate Dr Deepa Subramanyam, a researcher at the National Centre for Cell Science (NCCS) in the city. She has been studying stem cells for well over a decade, and has given talks on the subject. I have always been fascinated by how a handful of embryonic stem cells can create a perfectly patterned organism, says Subramanyam.

This weekend, Subramanyam has been invited as Science on Taps guest speaker. The scientists presentation is titled Godplayer stem cells, gene editing and playing god! Science on Tap was started as a talk series to connect the public with some of the countrys finest scientists in an informal setting. Anybody is welcome to attend the event regardless of their age and background. I avoid using scientific jargon to make my presentation accessible to the general public, she adds.

Subramanyam says that research on stem cells began about 30 years ago. She is certain that stem-cell therapy can treat most human ailments, such as diabetes and heart disease, in the near future. According to Subramanyam, trials are underway to determine the effectiveness of stem-cell therapy. She, however, cautions: I would say that one has to be careful about stem-cell therapy at the moment you should not undertake it without proper approval.

Subramanyam enjoys interacting with the public. In the past, she has addressed an audience comprising children, as part of an outreach programme. The talk was on stem cells. The scientist is always surprised by the intelligent questions that children ask her. Youngsters can come up with some of the most difficult questions, as they have access to a lot of information, says Subramanyam, who confesses that at times she has wondered how she should proceed to answer them.

WHERE: Mr Rabbits Bar & Burrow, Baner Road WHEN: September 28, 5 pm

See more here:
God of miniscule things - Pune Mirror

Platelet Rich Plasma (PRP) Market to Expand with Increasing Demand for Cosmetic Surgeries – The Midland Weekly

By Platelet Rich Plasma Injections

The Global Platelet Rich Plasma (PRP) Market is set to grow on account of increase in the occurrence of orthopedic and sports injuries. Key insights have been shared by Fortune Business Insights in its report, titled Platelet Rich Plasma Market Size, Share And Global Trend By Origin (Allogeneic, Autologous, Homologous), By Type (Pure PRP, Leukocyte rich PRP, Leukocyte rich fibrin), By Application (Orthopaedic surgery, Cosmetic surgery, General surgery, Neurosurgery, Others), And Geography Forecast Till 2026.

Get PDF Brochure of this [emailprotected] https://www.fortunebusinessinsights.com/enquiry/sample/platelet-rich-plasma-market-100581

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

North America to Make the Largest Contribution to the Market

The global platelet rich plasma market to rise on the shoulders of North America as the region is slated to hold the top position in terms of market share in the forecast period. High prevalence of sports injuries and orthopaedic surgeries coupled with high demand for cosmetic treatments are the factors that are expected to drive the market. In terms of CAGR, Asia-Pacific, primarily India and China, are anticipated to widen the market base. Main reasons identified for Asia-Pacific are the rising percentage of the population having rheumatology disorders. Added to this is the increasing demand of cosmetic surgeries and growing instances of sports injuries.

Browse Full [emailprotected] https://www.fortunebusinessinsights.com/industry-reports/platelet-rich-plasma-market-100581

The reports analyses the different factors influencing the growth of this market during the forecast period. Plasma is a part of blood that contains proteins that help in clotting of blood and support cell growth. Platelet-rich plasma is a substance that is injected into the body to accelerate healing. The basic idea is to stimulate the body to grow new and healthy cells by injecting the platelet-rich plasma into it. Cases where platelet-rich plasma injections are used include hair growth, tendon injuries, osteoarthritis, and post-surgical repair. It has also been applied to reduce inflammation and promote tissue healing.

Quality and Cost Issues Hampering the Rise of the Market

While the global platelet rich plasma market is on the threshold of experiencing rapid growth, it has to overcome certain hurdles. These are mainly in the form of high costs platelet-rich plasma therapies and poor quality control of test results. Moreover, the US Food and Drug Administration has not yet approved of the platelet-rich plasma treatments. Such hindrances are hampering the smooth rise of the global platelet rich plasma market.

Segmentation

By Origin

By Type

By Application

By Geography

More Trending Topics From Fortune Business [emailprotected]

Surgical Robots Market is Likely to Rise at a Staggering 21.4% CAGR by 2026

At 23.4% CAGR, Telehealth Market to Reach US$ 266.8 Bn by 2026

Go here to see the original:
Platelet Rich Plasma (PRP) Market to Expand with Increasing Demand for Cosmetic Surgeries - The Midland Weekly

49ers pass rusher Dee Ford will play through knee tendinitis this season – 49ers Webzone

By Platelet Rich Plasma Injections

Stan Szeto-USA TODAY Sports

The 49ers thought they had a handle on the situation by having Ford undergo platelet-rich plasma (PRP) injections during training camp. The problem resurfaced during the team's Week 2 matchup against the Cincinnati Bengals. Ford played just 16 snaps during San Francisco's win over the Pittsburgh Steelers on Sunday.

It sounds like Ford is preparing to just play through the discomfort this season, according to Eric Branch of the San Francisco Chronicle.

"[My knee] will never be 100 percent," Ford told The Athletic before the regular-season opener earlier this month. "It's enough. It's enough. I wouldn't step on the field if I wasn't ready."

The 49ers surrendered a 2020 second-round draft pick on March 12 to acquire Ford from the Kansas City Chiefs, and then quickly signed him to a new five-year deal. He has two sacks and a forced fumble through three games this season.

Ford, who is in his sixth NFL season, recorded career-highs of 13 sacks, 55 combined tackles, and seven forced fumbles last year with the Chiefs.

The rest is here:
49ers pass rusher Dee Ford will play through knee tendinitis this season - 49ers Webzone

Best Anti-Aging Tips and Products for Skin and Hair – HarpersBAZAAR.com

By Platelet Rich Plasma Injections

Your Skin StrategyAT HOME

Ask any dermatologist and theyll all tell you the number-one thing you need to do for your face is to apply sunscreen daily. The bare minimum for future-proofing your skin is the consistent use of a sunscreen with a minimum SPF of 30, says Annie Chiu, M.D., a dermatologist in Redondo Beach, California. And even if you have an office job, you need to reapply. A lot of people think reapplication is only necessary with sweating or sports activity, but the correct way of dosing sunscreen is actually multiple times a day, Chiu says. To make it easy, use a makeup setting spray like Supergoop! x Rebecca Taylor Defense Refresh Setting Mist SPF 50 before heading out to lunch.

Adding a layer of antioxidant serum under your SPF acts like a safety net, helping to trap anything that gets through your sunscreen, says Miami dermatologist Joely Kaufman, M.D. Vitamin C is a great option, though many doctors suggest a cocktail of ingredients, like those in 37 Actives High Performance Anti-Aging and Firming Serum.

Of course, the nighttime element of your skin-care routine is just as important as the morning one. Retinol does a great job of building up collagen in the dermis, says Robert Anolik, M.D., a dermatologist in New York. It also prevents excess pigmentation formation in the epidermis. If retinol is too irritating for you, try bakuchiol, which is perfect for sensitive complexions. Its a botanical extract that helps activate the same retinoid receptors that retinol binds to, says New York dermatologist Joshua Zeichner, M.D. Find it in Burts Bees Renewal Intensive Firming Serum.

Repetitive movement can lead to dynamic wrinkles, like frown lines between the brows, Chiu says. This is where preventive Botox comes in. It keeps muscles from being overactive and lines from becoming permanent. Once wrinkles etch, meaning you can see them when your face is relaxed, its too late for products like Botox to have full benefit, explains Chiu. So when to start? You may want to consider it if you see the residue of a crease in the minutes after youve been very expressive, says Anolik.

Laser treatments offer the best way to address sun damage before it manifests as dark spots. For people whose skin looks dull, whose pores arent as tight as they used to be, or have some broken blood vessels, the Clear + Brilliant fractionated laser is great, says Kaufman. It takes off that sun-damaged outer layer and allows a new layer to come up. According to Kaufman, improvements are visible after one treatment.

At the first signs of sagging, think about booking a radio frequency or ultrasound skin-tightening session, such as Thermage or Ultherapy. These target the deeper collagen layers that have a lifting effect, Anolik says. And because youre not letting this collagen age as it naturally wants to, the rate at which you become more laxand the rate and timing of possible future plastic surgerywill slow.

In the end, its all about consistency. Doing your at-home routine twice a day should be like brushing your teeth, says Macrene Alexiades, M.D., a dermatologist in New York. And seeing me two or three times a year is similar to visiting the dentist for a deep clean.

Sheer Zinc Face Lotion SPF 50

$12.99

UV Clear Facial Sunscreen

$35.00

Vitamin C Ceramide Capsules

$48.00

C E Ferulic

$128.99

Retinol 24 Night Facial Serum

Revitalift Cicacream

$17.99

Its not all in your head. If you look at your college graduation pictures and swear that your hair used to be thicker, shinier, and generally more fabulous, youre right. Genetically were programmed to have our best hair when were most fertile, says New York dermatologist Doris Day, M.D. After your mid-20s, hair starts to lose its luster: Strands are thinner, less pigmented, and often coarse. On the bright side, pros say you can slowand even reversesome of the signs of aging. Heres how.

Not only do older hair follicles produce strands that are finer, but they also make fewer of them. This can translate into a skinnier ponytail, a wider part, or a more visible scalp. Most doctors suggest a multipronged approach. I usually give patients vitamins that address hair loss associated with stress or hormonal fluctuations, says Francesca Fusco, M.D., a New York dermatologist. Her go-to: Nutrafol Core for Women, which contains antioxidants, adaptogens, and botanicals. Day recommends that in tandem with supplements, patients apply a topical 5 percent minoxidil foam daily (available as Womens Rogaine). In clinical studies, 81 percent of women regrew hair up to 48 percent thicker, she says. The earlier you start, the betterits easier to preserve the hair you have than it is to regrow it. Another pro pick: an FDA-cleared at-home laser helmet like Theradome Pro worn two or three times a week. The light produces cellular energy to help induce growth. (All of these treatments require maintenance.) More aggressive treatments include PRP (platelet-rich plasma) injections for four to six months to stimulate dormant follicles and, in severe cases, a transplant.

If youre not ready to go silver, prepare for a committed relationship with your colorist. The average client comes in every four weeks, says Kyle White, a colorist at New Yorks Oscar Blandi salon. Coarse hair is more difficult to cover, but, paradoxically, dyeing hair can improve the texture. The chemicals make strands more pliable, explains White. Clients notice their gray roots getting wiry, and once we touch them up theyre more manageable. Highlights are an additional option to consider because they provide a flattering contrast between hair and skin. And because youre investing all that time coloring your hair, ensure lasting results by using a color-safe shampoo and conditioner, such as LOral Paris EverPure Repair & Defend Shampoo and Conditioner.

When hair shrinks in diameter and loses pigment, its structure also changes: Hair is both coarser and more fragile. According to Joe Martino, creative director of New Yorks Orlo Salon, the solution is hydration. People are afraid to weigh down thin hair with an oil, says Martino. Its actually the best thing for mature hair. Since the scalp produces less oil, conditioning strengthens hair and gives it shine. Use a deep-conditioning masklike Love Beauty and Planet 2 Minute Magic Masqueweekly, as well as argan oil, such as Moroccanoil Pure Argan Oil, to tame wiry strands. Work a few drops through dry hair. Pure argan oil wont weigh down hairand really does make it look younger.

Laser Hair Growth Helmet

$895.00

Repair and Defend Conditioner

$7.99

Hair Loss Thinning Supplement

$88.00

2 Minute Magic Masque

$3.49

Pure Argan Oil

$52.00

Repair & Defend Shampoo

$7.99

Read the original:
Best Anti-Aging Tips and Products for Skin and Hair - HarpersBAZAAR.com

Mansfield’s Daniel Maberry has returned to coaching during battle with cancer, but his stay on sideline will be brief – The Dallas Morning News

By Stem Cell Doctors

Mansfield football coach Daniel Maberry was forced to take an 11-month break from coaching games as he battled an incurable disease.

The last two weeks, Maberry was finally feeling well enough that he could pause his fight with cancer and coach his first two games of the season. His return to the sideline will be brief, however.

The 47-year-old Maberry said Tuesday night that he hopes to coach Friday when Mansfield (1-3, 0-1 District 7-6A) plays South Grand Prairie (2-2, 1-0) at 7:30 p.m. at the Gopher-Warrior Bowl in Grand Prairie. But that will be his last game of the season, as he prepares to begin eight weeks of treatment in early October, with the first two weeks spent in the hospital.

"I plan to be on the sideline [Friday], but it will depend on what I can do," he said.

Maberry coached last Friday after getting radiation treatment earlier in the day. "It zaps you," he said, but he handled the head coaching duties while interim coach Greg George returned to his role as offensive coordinator.

"It was awesome," said Maberry, who had to take a break from coaching last season after Mansfield's game against DeSoto on Oct. 12, 2018. "Having an opportunity to coach my kids and be excited with them. I had been away from it for too long."

Sign up for our FREE HS newsletter!Subscribe today for as little as $5 a month!

Maberry was diagnosed with Stage 4 lymphoma in January 2018, but in June of that year doctors told him that his disease was basically in remission, and had become "inactive." That wouldn't be the last time he would hear that, only to see the lymphoma return.

Three to four months later, Maberry's disease had morphed into an aggressive form of non-Hodgkin's lymphoma called diffuse large B-cell lymphoma. After undergoing chemotherapy, Maberry was told in March that he was clear of it, that it was back in remission.

Maberry had a stem cell transplant in April, only for doctors to detect a small spot on his rib cage in early August. He started radiation treatment last week, but he's not giving up and credits his family and the Mansfield community with helping him throughout the grueling ordeal.

"God has used a lot of people to pick me up," he said. "It has been a kick in the gut every single time. It has been incredibly hard, but I can't allow this to rob me of my joy. I feel like I am going to get better. My faith is strong."

Twitter: @DMNGregRiddle

More here:
Mansfield's Daniel Maberry has returned to coaching during battle with cancer, but his stay on sideline will be brief - The Dallas Morning News

Eyes on the Prize: The CBC Fights Blindness During Sickle Cell Awareness Month – The Root

By Stem Cell Doctors

Blood is the jet fuel of the body. It helps you jump, run, breathe and move with ease through the world. So imagine what happens if that fuel isnt running smoothly through your body. Its clogging your system, straining every valve, organ and extremity as youre slowly starved for air. That sounds excruciatingly painful, and thats exactly what 1 in 365 African Americans deal with who suffer from sickle cell anemia.

September is Sickle Cell Awareness Month and its common throughout the month to see awareness raising articles about famous people living with sickle cell, like actor Larenz Tate (Power), T-Boz from TLC, former Giants running back Tiki Barber or even Howard University President Wayne Frederick. You seldom see stories about what actions are being taken by scientists and researchers to make sickle cell disease and the dozens of medical consequences that stem from it a thing of the past. Thats why Rep. Sanford Bishop (D-Ga.) and the Congressional Black Caucus have decided to do something about it.

The reason most peoples blood runs smoothly through their bodies is that red blood cells are round and smooth, which allows them to slip through blood vessels with ease. For those with sickle cell, red blood cells have hardened into a C shape, (thus the sickle name); they clog the bloodstream and choke off vital oxygen to organs, causing pain, organ failure and, in some cases, death.

When a child is diagnosed with sickle cellsometimes even toddlersdoctors often warn parents about the childs potential limitations and prescribe proper therapy and medication to make sure he or she lives a long and healthy life. Unfortunately, like many other areas of the American healthcare system, not enough attention is paid to a disease that primarily affects African Americans, and many of the other consequences of sickle cell get missed.

Sickle cell retinopathy is overlooked by most pediatricians but even some specialized doctors, says Morton Goldberg, the director emeritus of the Wilmer Eye Institute at Johns Hopkins University in Baltimore. Dr. Goldberg has the tone of a man who has been in the trenches for years and is finally seeing a turning point in the war. He has been working on sickle cell retinopathy for over 50 years and talks about how the disease, because it is most common in African Americans, is often overlooked even though the consequences are utterly dire and easily preventable.

For the layman, sickle cell retinopathy is when the diseased blood cells cause clogging in the blood vessels around the eye, which can lead to a host of other complications, the most serious being blindness. There is equipment out there, even training that can help doctors diagnose sickle cell retinopathy early to give parents and patients the tools they need, but that need usually goes unmet. Why?

Theres been insufficient funding for the last 30 to 40 years, says Dr. Goldberg, which is why hes on board to promote H.R. 2620, the Faster Treatments and Cures for Eye Diseases Act proposed by Bishop.For far too long, we have had federally funded research sitting on the shelf, waiting for private investors to put it into practice, Congressman Bishop said. When it comes to turning research into cures, we must seek new ways to tackle old problems. The Eye bonds created by the Faster Treatments and Cures for Eye Diseases Act will give health research the boost it needs to help Americans. These bonds will fund research that has the potential to deliver new treatments for a range of conditions, including macular degeneration, glaucoma, blindness caused by diabetes and sickle cell disease, and many others. And this is just the first step, if this pilot program is successful, a similar approach could be used to support groundbreaking research for other conditions such as cancer, Alzheimers and Parkinsons disease.

Money is, of course, one of the main reasons why research into preventing blindness caused by other diseases often doesnt go anywhere or doesnt go far enough, especially when those suffering are from underserved communities to begin with. On top of blindness caused by sickle cell, retinopathy from diabetes causes 17 percent of vision loss in African Americansand blindness caused by glaucoma is twice as likely (3.4 percent) in African Americans as it is in white Americans (1.7 percent).

A lot of this is about access to care, says Dr. Carlton Haywood, a professor of biomedical ethics at Johns Hopkins. The bill proposed by Rep. Bishop has particular resonance with Haywood since he actually has sickle cell and has spent much of his career focusing on the impact of care and access for blood-borne diseases. Haywood, who was also a former patient of Dr. Goldberg, points out that even when a doctor may advise a family to look into the possibility of retinopathy, without funding for even the diagnosis, preventive or corrective surgeries could be astronomical.

All too often, the press and regular voters talk about all the things that Congress doesnt do. In the process, we forget about the kind of day-to-day grind work that members of Congress do every day to help people not just in their districts but across the nation.. The Faster Treatment and Cures for Eye Diseases Act is the kind of thing that everyone says they want Congress to pass (who isnt against blindness?), but it currently sits in the Energy and Commerce Committee, waiting for a vote in committee so that it can be voted on by the entire House. This is the kind of bill America wants to see, and this bill, both figuratively and literally, can make that happen.

View original post here:
Eyes on the Prize: The CBC Fights Blindness During Sickle Cell Awareness Month - The Root

→←